Close Menu

NEW YORK (GenomeWeb) – Grail and Cirina, two startups looking to commercialize liquid biopsy tests for early cancer detection, have decided to join forces.

Cirina, which was founded by Dennis Lo of the Chinese University of Hong Kong and raised $12 million in a Series A financing round in 2014, will operate as a subsidiary of Grail.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.